MedPath

PREMAPROB. Probiotics to Prevent Necrotizing Enterocolitis

Not Applicable
Completed
Conditions
Necrotizing Enterocolitis
Premature Infants
Interventions
Dietary Supplement: High dose group
Dietary Supplement: Low dose group
Registration Number
NCT06501404
Lead Sponsor
José Antonio Hurtado Suazo
Brief Summary

The main objective of this study is to assess the impact of two different doses of a mixture of probiotics from two strains isolated in human milk on the incidence of severe necrotizing enterocolitis (NEC) and death among preterm infants of gestational age less than or equal to 32 weeks of gestation and weighing between 750 and 1500 g.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
583
Inclusion Criteria
  • Preterm infants of gestational age less than 33 weeks of gestation with birth weight below 1500 g, admitted to the Neonatology Unit.
  • Premature newborns who meet the above criteria and receive enteral feeding (mother breast milk, donors milk and/or premature formula) from the amount of 5 ml/kg/day.
Exclusion Criteria
  • Any clinical circumstance that prevents the initiation of enteral nutrition in the first 72 hours of life.
  • Chromosomopathies and complex fetal malformations, incompatible with enteral nutrition in the first 72 hours of life.
  • Non-acceptance of informed consent to participate in the study by the parents or legal guardians of the newborn.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
High dose of probiotic mixtureHigh dose groupA daily high dose of a mixture of probiotics (Lactobacillus Fermentum CECT 5716 and Bifidobacterium breve CECT 7263), was given orally starting in the first 72 hours of life, until 36+6 weeks of postmenstrual age or discharge The total dose was 1x109 CFU of each of the strains
Low dose of probiotic mixtureLow dose groupA daily low dose of a mixture of probiotics (Lactobacillus Fermentum CECT 5716 and Bifidobacterium breve CECT 7263), was given orally starting in the first 72 hours of life, until 36+6 weeks of postmenstrual age or discharge The total dose was 1x106 CFU of each of the strains
Primary Outcome Measures
NameTimeMethod
Incidence of necrotizing enterocolitis and all-cause mortalityFrom birth until three months

The primary objective of the study was to determine the incidence of necrotizing enterocolitis (modified Bell classification stages II and III) and all-cause mortality during hospital stay in both intervention groups.

Secondary Outcome Measures
NameTimeMethod
Incidence of Bronchopulmonary DysplasiaFrom birth until three months
Incidence of patent ductus arteriosusFrom birth until three months
Intestinal colonization by administered strainsFrom birth until three months
Days of Central Vascular CatheterFrom birth until three months
Time to complete enteral nutritionFrom birth until three months

Time to reach complete enteral nutrition 140 ml/kg/day

Incidence of Late Onset SepsisFrom birth until three months

Incidence of Late Onset Sepsis. In accordance with the criteria used by the Castrillo Group for neonatal infections in Spain (compatible clinical symptoms, elevation of water-phase reactants and positive blood culture)

Length of hospital stayFrom birth until three months

Days of hospital stay

Weight changeFrom birth until three months

Trial Locations

Locations (1)

Hospital Virgen de las Nieves

🇪🇸

Granada, Spain

© Copyright 2025. All Rights Reserved by MedPath